Inimmune Commences Pivotal Phase 2 Allergy Trial of INI-2004 in Allergic Rhinitis Patients
Missoula, Montana – January 7, 2026 – Inimmune Corporation (“Inimmune”), a clinical-stage biotechnology company focused on developing innovative immunotherapies, today announced the start of its pivotal Phase 2 clinical trial evaluating INI-2004 in patients with allergic rhinitis. The Phase 2 study is a randomized, double blind, placebo-controlled allergen chamber trial being conducted in Kingston, Ontario, […]
Inimmune participates in the development of an innovative intranasal influenza vaccine
Inimmune is part of a European consortium, led by the Medical University of Vienna, whose goal is to develop a next-generation vaccine against influenza strains with pandemic potential The consortium aims to be selected under the European Commission’s EU4Health programme Girona, Spain — 24 November 2025 — – Inimmune, a leading clinical stage biotech company […]
Inimmune To Present On Their Next Generation Adjuvants At World Vaccine Congress in Amsterdam
Missoula, MT — October 1st, 2025 — Inimmune, a biotechnology company pioneering novel vaccine adjuvants, immunotherapies, and delivery systems, announced today that its leadership team will deliver multiple presentations at the World Vaccine Congress (WVC) in Amsterdam, Netherlands, October 13–16, 2025. David Burkhart, Ph.D., CEO of Inimmune, will speak at the Vaccine Delivery Workshop on […]
Inimmune to Present Trial-in-Progress Poster on First-in-Human Study of INI-4001, a Novel TLR7/8 Agonist, at ASCO 2025
Missoula, MT, May 29, 2025 – Inimmune Corporation, a clinical-stage biotechnology company focused on developing next-generation immunotherapies, today announced that it will present a Trial-in-Progress poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30–June 3, 2025, in Chicago, IL. The poster, titled “A first-in-human phase 1 clinical trial […]
Inimmune to Present Key Updates at the 2025 World Vaccine Congress in Washington, DC April 21-24
Missoula, MT, April 15, 2025 – Inimmune, a clinical-stage biotechnology company specializing in next generation vaccine adjuvants, immunotherapies, and delivery systems, is excited to announce its participation in the 2025 World Vaccine Congress, taking place April 21–24 in Washington, DC. The company will share exciting progress from its clinical-stage immunotherapy and vaccine programs, and take […]
Inimmune Welcomes Dr. Heather Madsen of Hatteras Venture Partners to Board of Directors
Missoula, MT, February 28, 2025 – Inimmune Corporation, a clinical-stage biotechnology company specializing in next-generation immunotherapies, is pleased to announce the appointment of Dr. Heather Madsen to its Board of Directors. Dr. Madsen, a distinguished life sciences executive and Operating Partner at Hatteras Venture Partners, brings extensive expertise in the creation of high-performing life science […]
Inimmune to present successful Phase I allergy trial results at the American Academy of Allergy Asthma & Immunology meeting in San Diego, February 28-March 3, 2025
Missoula, MT, February 26, 2025 – Inimmune Corporation, a clinical-stage biotechnology company specializing in next-generation immunotherapies for cancer, allergy, autoimmunity, and vaccines will attend the AAAAI meeting in San Diego from February 28-March 3 where Dr. Jay Evans, Inimmune’s Chief Scientific and Strategy Officer, will provide an update on Inimmune’s clinical stage treatment for seasonal […]
SPI Pharma, Inc. and Inimmune, Corp. Launch Partnership to Commercialize Advanced Adjuvant Systems
Wilmington, Delaware, October 22, 2024 – SPI Pharma, Inc., a global leader in biopharmaceutical excipient and adjuvant systems, and Inimmune, Corp., a pioneering biotechnology company specializing in the discovery and development of innate immune modulators, finalized their partnership to bring two adjuvant systems to market. The partners will launch these novel adjuvant systems at the […]
Insilico Medicine and Inimmune Achieved collaboration to Revolutionize Immunotherapy with AI-Driven Drug Discovery
Cambridge, Mass, September 13, 2024 – Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the company has achieved a groundbreaking collaboration with Inimmune, which will utilize Chemistry42, Insilico’s proprietary generative artificial intelligence (AI) technology to accelerate the discovery and development of next-generation immunotherapeutics. Chemistry42, a multi-agent reinforcement learning system designed […]
Inimmune Announces First Cancer Patient Dosed in Phase 1 Clinical Study Using the Immunotherapeutic INI-4001, a Novel TLR7/8 Agonist
MISSOULA, Montana, July 24, 2024 – Inimmune, a clinical stage biotech company focused on the development of novel immunotherapies, vaccines, and vaccine adjuvants announced today the dosing of the first patient in its Phase 1 single ascending dose study of INI-4001 in patients with advanced solid tumors. This is an open-label, multiple-ascending dose, two-part dose […]
